379 related articles for article (PubMed ID: 17208200)
1. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
Wiemer AJ; Tong H; Swanson KM; Hohl RJ
Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of a series of aromatic bisphosphonates.
Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326
[TBL] [Abstract][Full Text] [Related]
3. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
[TBL] [Abstract][Full Text] [Related]
4. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.
Wiemer AJ; Yu JS; Shull LW; Barney RJ; Wasko BM; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Apr; 16(7):3652-60. PubMed ID: 18308574
[TBL] [Abstract][Full Text] [Related]
5. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.
De Schutter JW; Zaretsky S; Welbourn S; Pause A; Tsantrizos YS
Bioorg Med Chem Lett; 2010 Oct; 20(19):5781-6. PubMed ID: 20801032
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.
Dudakovic A; Wiemer AJ; Lamb KM; Vonnahme LA; Dietz SE; Hohl RJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):1028-36. PubMed ID: 18083912
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
Wasko BM; Dudakovic A; Hohl RJ
J Pharmacol Exp Ther; 2011 May; 337(2):540-6. PubMed ID: 21335425
[TBL] [Abstract][Full Text] [Related]
8. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.
Wasko BM; Smits JP; Shull LW; Wiemer DF; Hohl RJ
J Lipid Res; 2011 Nov; 52(11):1957-64. PubMed ID: 21903868
[TBL] [Abstract][Full Text] [Related]
9. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
10. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Thompson K; Dunford JE; Ebetino FH; Rogers MJ
Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
[TBL] [Abstract][Full Text] [Related]
11. The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation.
Weivoda MM; Hohl RJ
J Cell Biochem; 2011 Jun; 112(6):1506-13. PubMed ID: 21503955
[TBL] [Abstract][Full Text] [Related]
12. Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation.
Agabiti SS; Li J; Wiemer AJ
Cell Death Dis; 2017 Mar; 8(3):e2678. PubMed ID: 28300835
[TBL] [Abstract][Full Text] [Related]
13. Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration.
Dudakovic A; Tong H; Hohl RJ
Invest New Drugs; 2011 Oct; 29(5):912-20. PubMed ID: 20480384
[TBL] [Abstract][Full Text] [Related]
14. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
16. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.
Reilly JE; Zhou X; Tong H; Kuder CH; Wiemer DF; Hohl RJ
Biochem Pharmacol; 2015 Jul; 96(2):83-92. PubMed ID: 25952057
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of isoprenoid bisphosphonates.
Shull LW; Wiemer AJ; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2006 Jun; 14(12):4130-6. PubMed ID: 16517172
[TBL] [Abstract][Full Text] [Related]
19. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
Savino S; Toscano A; Purgatorio R; Profilo E; Laghezza A; Tortorella P; Angelelli M; Cellamare S; Scala R; Tricarico D; Marobbio CMT; Perna F; Vitale P; Agamennone M; Dimiccoli V; Tolomeo A; Scilimati A
Eur J Med Chem; 2018 Oct; 158():184-200. PubMed ID: 30216851
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
